Shares of Applied DNA Sciences Inc (APDN) are currently trading at 2.7650 with a gain of over $0.7650 (+38.2500%). The stock is talk of the town owing to its recent news that it has received its largest single purchase order for LinearDNA valued above the mid-six figures. Based on the PR, the company will deliver quantities of LinearDNA to the customer in the current quarter, with the full order expected to be fulfilled over the subsequent three quarters.
The reason we think APDN will keep surging
If we look at the earnings, APDN had missed its Q3 and Q4 2021 by $0.23 and $0.36 respectively. However, in Q1 and Q2 2022, APDN beat the analysist consensus EPS by @0.10 and $0.22. Considering the large, latest order of LinearDNA, APDN may very well be on the line to beat its Q3 EPS. Shares are currently trading well below the 52 week high of $7.35.
Earlier this month, APDN had announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a LinearDNA™-based vaccine candidate reduced infectious virus shedding and was protective against SARS-CoV-2 in a challenge trial in ferrets. The purpose of the challenge trial was to demonstrate that LinearDNA-based vaccines can express therapeutic antigens that can confer protection against infection.
Other companies in Air Products & Chemicals’s space includes: DuPont de Nemours (NYSE:DD), Corteva (NYSE:CTVA), PPG Indus (NYSE:PPG), Intl Flavors & Fragrances (NYSE:IFF) and RPM International (NYSE:RPM).
